Coglapix® Editions

Inactivated vaccine against swine pleuropeumonia caused by Actinobacillus pleuropeumoniae

Coglapix Edition 1

A field trial performed with Coglapix® in The Netherlands is described in a farm presenting Actinobacillus pleuropneumoniae infection.

Using a veterinary application, “VetApp”, which has been developed to follow-up the health status on pig farms during the monthly farm visits, a reduction of the coughing index has been associated with a drop of mortality by approximately 50% and the antibiotic use was reduced to almost zero after the introduction of the vaccine.

>>>>>>>To Read More please , click to download the complete Study 

Coglapix Edition 2

The distribution of various serotypes of Actinobacillus pleuropneumoniae differs substantially among countries.

The presence of various serotypes in a farm as well as in a given area doesn’t stay stable, but evolves over the time.

Serotype 8 is the most prevalent in the UK and was isolated also in other countries as highly virulent. In an experimental challenge trial, Coglapix® documented high efficacy against the serotype 8 of A. pleuropneumoniae.

There was the lowest rate of clinical symptoms and no mortality in pigs vaccinated with Coglapix®.

>>>>>>>To Read More please , click to download the complete Study 

From one country to another, product lines are adapted to local demand and regulatory requirements. For further information, please take a look at the CEVA Santé Animale site for your country. Warning: the information provided on the products depends on national registrations. Access to technical information is restricted to authorised persons.

Back to top